Is Ultragenyx Stock a Buy After GTX-102 Flop? Analysts Point to Commercial Pipeline
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"Is Ultragenyx Stock a Buy After GTX-102 Flop? Analysts Point to Commercial Pipeline" is generating significant coverage in the Business category, with 5 articles from 5 distinct sources tracked by PULSE so far.
Outlets currently covering the story include MarketBeat, finance.yahoo.com, STAT and Fierce Biotech. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 63d ago.
Quick answers
Why is "Is Ultragenyx Stock a Buy After GTX-102 Flop? Analysts Point to Commercial Pipel" trending?
Because 5 independent news sources published 5 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (13)
- RARE Stock Heads For Record Low: Angelman Trial Miss Leads To Wall Street Downgrades Yahoo Finance · 63d ago
- Ultragenyx vows 'significant' cuts after experimental rare-disease drug flunks late-stage clinical trial The Business Journals · 63d ago
- Why Did RARE Stock Slump 46% After-Hours? Yahoo Finance · 63d ago
- Ultragenyx drug to treat Angelman syndrome, a rare disease, fails late-stage trial STAT · 63d ago
- Ultragenyx to weigh ‘significant’ cost cuts as Angelman drug fails key study BioPharma Dive · 63d ago
- Ultragenyx to slash costs after Angelman trial failure pharmaphorum · 63d ago
- Ultragenyx mulls fate of rare disease programme on Phase III flop Clinical Trials Arena · 63d ago
- Ultragenyx Pharmaceutical (NASDAQ:RARE) Rating Lowered to "Equal Weight" at Wells Fargo & Company MarketBeat · 63d ago
- Ultragenyx Shares Fall After Phase 3 Aspire Study Misses Primary Endpoint finance.yahoo.com · 63d ago
- We’re reading about an Ultragenyx failure, RevMed for lung cancer, and more STAT · 63d ago
- Ultragenyx fails phase 3 Angelman test, plots ‘significant expense reductions’ Fierce Biotech · 63d ago
- Is Ultragenyx Stock a Buy After GTX-102 Flop? Analysts Point to Commercial Pipeline Barron's · 63d ago
- Ultragenyx's ASO fails in Angelman syndrome, triggering sell-off FirstWord PHARMA · 63d ago
Topics
Related trends
Sandisk: A 35% Stock Decline, But RPO Tells A Different Story (Rating Upgrade)
2 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Stock Market Today: Nasdaq Sinks 4% as Investors Ditch Chip, Data-Center Stocks
4 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Stock Market Today: Rotation Away From AI Stocks Increases as Money Flows to AI Landlords
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
SpaceX Stock Today Has These 2 Positives. The Stock Is Still Falling.
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Nvidia Stock Is Back at $200. What History Suggests Is the Floor.
6 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Stock market today: Dow, S&P 500, Nasdaq plunge in dramatic reversal, giving back post-election rally gains
3 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.